1Hoshikawa Y, Voelkel N F, Gesell T L, et al. Prostacyclin receptor dependent modulation of pulmonary vascular remodeling [J]. Am J Respir Crit Care Med, 2001, 164 (2): 314-318.
2Tuder R M, Cool C D, Geraci M W, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension [J]. Am J Respir Crit Care Med, 1999, 159 (6): 1925-1932.
3Tetsuo A, Taisuke H, Yukiteru S, et al. Structure-activity studies on diphenylpyrazine derivatives: A novel class of prostacyclin receptor agonists [J]. Bioorg Med Chem, 2007, 15 (21): 6692-6704.
5Keiichi K, Asami H, Tetsuo A, et al. 2-{4-[(5, 6-Diphenyl- pyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide (NS-304), an orally available and long-acting prostaeyclin receptor agonist prodrug [J]. J Pharmaeol Exp Ther, 2007, 322 (3): 1181-1188.
6Keiichi K, Asami H, Kumiko N, et al. A long-acting and highly selective prostaeyclin receptor agonist prodrug, 2-{4-[(5,6- Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy } -N-(methyl-sulfonyl) acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy} acetic acid (MRE-269), on rat pulmonary artery [J]. J Pharmacol Exp Ther, 2008, 326 (3): 691-699.
7Informa UK Ltd. Selexipag//Pharmaprojects V5 [DB/OL]. [2010-09-29]. http://pharma vicp.net/MenuFrame.aspx.
8Actelion Pharma. Actelion announces presentation of positive phase Ⅱ results with selexipag in patients with pulmonary arterial hypertension at the American Thoracic Society 2010 International Conference [DB/OL]. ( 2010-05-17) [2010-09-16]. http://www.actelion.com/en/our-company/news-and-events/ index, page? newsld = 1416340.
